All In Biotech

Free tool

FAERS Monitor: Thermazene

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 018810 or its brand name (Thermazene, Silver Sulfadiazine). Reports on generic versions are filed under their own applications.

Reports

1,402

Serious

925

66% of reports

Hospitalization

470

Death reported

173

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product use in unapproved indication133
  • off label use113
  • pain95
  • chronic kidney disease86
  • fatigue84
  • drug ineffective77
  • death71
  • acute kidney injury66
  • diarrhoea66
  • nausea64
  • anxiety62
  • pneumonia61
  • rash59
  • renal failure57
  • fall55

Reports by year received

View as table
YearReports
20049
200514
200611
200716
20084
200916
201013
201117
201234
201322
201431
201537
201679
201773
2018106
2019116
2020125
2021173
2022126
2023113
202488
202585
202693

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,757 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic kidney diseaseSignal8617.013.81,282
product use in unapproved indicationSignal1338.16.9824
acute kidney injurySignal666.55.1302
renal failureSignal576.45.0258
anxietySignal623.32.697
pneumoniaSignal612.82.271
fallSignal552.51.948
painSignal952.31.972
rashSignal592.01.630
off label use1131.91.652
fatigue841.61.320
diarrhoea661.51.212
death711.21.03
nausea641.21.02
drug ineffective770.90.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.